CFTR and cystic fibrosis: In the setting of CF, preclinical investigations indicate ASO-dependent silencing of SMG1 or SMG6 significantly increases transcript expression, protein trafficking, and transepithelial ion transport of CFTR nonsense variants (Keenan et al., 2019; Sanderlin et al., 2022).